Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4)	Bristol-Myers Squibb Company / Balsam CRO	Ongoing	Adagrasib(BMS-986503/KRAZATI®)	3	CA2390004	King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh)
Phase 3 study to evaluate the efficacy and safety of zodasiran in adolescent and adult subjects with homozygous familial hypercholesterolemia (YOSEMITE)	Arrowhead Pharmeceuticals, Inc. / Balsam	Ongoing	Zodasiran	3	AROANG3-3001	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination with Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer.	Merck Sharp &Dohme KSA	Ongoing	Sacituzumab and Pembrolizumab	3	MK-6482-033-01	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 3, Open-label, Randomized, Controlled Trial of Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults with Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukaemia	Amgen Inc./ IQIVIA	Ongoing	Blinatumomab	3	20240113	King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh)
The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients with Moderate-to-Severe Atopic Dermatitis in Gulf Countries: DERMIND-AD	Sanofi	Ongoing	Dupilumab	4	OBS18647	Fakeeh Medical Center (Jeddah)
An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination with Pembrolizumab Compared with Pembrolizumab Monotherapy as First-Line Treatment in Participants with PD-L1 High (≥50% Of Tumor Cel Expressing Pd-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer.	Pfizer	Ongoing	Sigvotatug Vedotin and Pembrolizuma	3	C5751003	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2/3, Open-Label, Randomized, Controlled, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, Versus Ongoing Standard-Of-Care Immunosuppressive Therapy in Patients with Generalized Myasthenia Gravis (KYSA-6).	Kyverna Therapeutics, Inc. / Balsam	Ongoing	KYV101	2	KYV101-006	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705	Moderna TX,Inc./ Balsam	Ongoing	MRNA 3705	2	mRNA-3705-P101-EXT	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype	Sanofi Arabia Trading Company Limited / ArabMed CRO	Ongoing	Lunsekimig	2	EFC18243	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Medical City (Riyadh)
A Multi-Center, Non-Interventional Study on Effectiveness and Treatment Persistence of Guselkumab in Patients with ULcerative Colitis and Crohn’s DiseasE in Real-World Practice in Saudi Arabia (EAGLE)	Johnson & Johnson / IQIVIA	Ongoing	Guselkumab( Tremfya)	4	CNTO1959IB	Al Salama Hospital (Jeddah)